Close monitoring of patients ensures outcomes, savings
ORLANDO, Fla. – Close monitoring of hemophilia patients ensures bleed rate stays low and the patients can be managed with less factor VIII, according to a study by Option Care being presented at the World Federation of Hemophilia 2016 World Congress meeting today. That, in turn creates significant cost savings without affecting patient outcomes. “By working with prescribers to closely monitor bleeds and collaborate on clinically appropriate optimization of treatment dose, Option Care’s utilization of factor VIII is less than the average with excellent outcomes,” said Joan Couden, national program director for Option Care’s Bleeding Disorders Program. “Our findings show we can save payers, including Medicare, Medicaid and managed care insurers, significant costs without negatively impacting annual bleed rates.” The Option Care study included 77 hemophilia A patients receiving home infusion of factor VIII.